vs
Side-by-side financial comparison of HCI Group, Inc. (HCI) and IDEAYA Biosciences, Inc. (IDYA). Click either name above to swap in a different company.
HCI Group, Inc. is the larger business by last-quarter revenue ($246.2M vs $207.8M, roughly 1.2× IDEAYA Biosciences, Inc.). IDEAYA Biosciences, Inc. runs the higher net margin — 57.4% vs 39.7%, a 17.7% gap on every dollar of revenue. HCI Group, Inc. produced more free cash flow last quarter ($440.8M vs $142.2M).
HCI Equity Partners is a Washington, DC–based private equity firm with an additional office in Chicago, Illinois.
IDEAYA Biosciences, Inc. is a clinical-stage biotechnology company focused on oncology, developing targeted therapies and synthetic lethality treatments for patients with genetically defined cancers. It advances a pipeline of candidates across multiple tumor types, partnering with industry stakeholders to accelerate global access to innovative cancer care solutions.
HCI vs IDYA — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $246.2M | $207.8M |
| Net Profit | $97.7M | $119.2M |
| Gross Margin | — | — |
| Operating Margin | 58.5% | 52.2% |
| Net Margin | 39.7% | 57.4% |
| Revenue YoY | 52.1% | — |
| Net Profit YoY | 3679.2% | 330.1% |
| EPS (diluted) | $7.29 | $1.33 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $246.2M | — | ||
| Q3 25 | $216.3M | $207.8M | ||
| Q2 25 | $221.9M | — | ||
| Q1 25 | $216.4M | — | ||
| Q4 24 | $161.9M | — | ||
| Q3 24 | $175.3M | $0 | ||
| Q2 24 | $206.2M | $0 | ||
| Q1 24 | $206.6M | $0 |
| Q4 25 | $97.7M | — | ||
| Q3 25 | $65.5M | $119.2M | ||
| Q2 25 | $66.2M | — | ||
| Q1 25 | $69.7M | — | ||
| Q4 24 | $2.6M | — | ||
| Q3 24 | $5.7M | $-51.8M | ||
| Q2 24 | $54.1M | $-52.8M | ||
| Q1 24 | $47.6M | $-39.6M |
| Q4 25 | 58.5% | — | ||
| Q3 25 | 41.9% | 52.2% | ||
| Q2 25 | 42.5% | — | ||
| Q1 25 | 46.4% | — | ||
| Q4 24 | 3.6% | — | ||
| Q3 24 | 8.0% | — | ||
| Q2 24 | 36.9% | — | ||
| Q1 24 | 37.5% | — |
| Q4 25 | 39.7% | — | ||
| Q3 25 | 30.3% | 57.4% | ||
| Q2 25 | 29.8% | — | ||
| Q1 25 | 32.2% | — | ||
| Q4 24 | 1.6% | — | ||
| Q3 24 | 3.2% | — | ||
| Q2 24 | 26.2% | — | ||
| Q1 24 | 23.0% | — |
| Q4 25 | $7.29 | — | ||
| Q3 25 | $4.90 | $1.33 | ||
| Q2 25 | $5.18 | — | ||
| Q1 25 | $5.35 | — | ||
| Q4 24 | $0.32 | — | ||
| Q3 24 | $0.52 | $-0.60 | ||
| Q2 24 | $4.24 | $-0.68 | ||
| Q1 24 | $3.81 | $-0.53 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.2B | $786.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.0B | $1.1B |
| Total Assets | $2.5B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.2B | — | ||
| Q3 25 | $987.9M | $786.9M | ||
| Q2 25 | $947.2M | — | ||
| Q1 25 | $754.5M | — | ||
| Q4 24 | $532.5M | — | ||
| Q3 24 | $518.8M | $920.0M | ||
| Q2 24 | $445.8M | $701.7M | ||
| Q1 24 | $655.4M | $698.8M |
| Q4 25 | $1.0B | — | ||
| Q3 25 | $821.8M | $1.1B | ||
| Q2 25 | $758.6M | — | ||
| Q1 25 | $522.7M | — | ||
| Q4 24 | $453.3M | — | ||
| Q3 24 | $455.3M | $1.2B | ||
| Q2 24 | $447.3M | $931.7M | ||
| Q1 24 | $395.7M | $935.3M |
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.3B | $1.2B | ||
| Q2 25 | $2.4B | — | ||
| Q1 25 | $2.3B | — | ||
| Q4 24 | $2.2B | — | ||
| Q3 24 | $2.0B | $1.2B | ||
| Q2 24 | $1.9B | $973.7M | ||
| Q1 24 | $1.8B | $961.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $444.4M | $142.2M |
| Free Cash FlowOCF − Capex | $440.8M | $142.2M |
| FCF MarginFCF / Revenue | 179.0% | 68.4% |
| Capex IntensityCapex / Revenue | 1.5% | 0.0% |
| Cash ConversionOCF / Net Profit | 4.55× | 1.19× |
| TTM Free Cash FlowTrailing 4 quarters | $771.4M | $13.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $444.4M | — | ||
| Q3 25 | $26.7M | $142.2M | ||
| Q2 25 | $145.0M | — | ||
| Q1 25 | $162.0M | — | ||
| Q4 24 | $331.8M | — | ||
| Q3 24 | $104.1M | $-49.2M | ||
| Q2 24 | $-29.0M | $-32.9M | ||
| Q1 24 | $182.0M | $-43.8M |
| Q4 25 | $440.8M | — | ||
| Q3 25 | $25.9M | $142.2M | ||
| Q2 25 | $144.5M | — | ||
| Q1 25 | $160.3M | — | ||
| Q4 24 | $327.8M | — | ||
| Q3 24 | $103.2M | $-49.7M | ||
| Q2 24 | $-30.1M | $-33.9M | ||
| Q1 24 | $181.0M | $-45.1M |
| Q4 25 | 179.0% | — | ||
| Q3 25 | 12.0% | 68.4% | ||
| Q2 25 | 65.1% | — | ||
| Q1 25 | 74.1% | — | ||
| Q4 24 | 202.5% | — | ||
| Q3 24 | 58.9% | — | ||
| Q2 24 | -14.6% | — | ||
| Q1 24 | 87.6% | — |
| Q4 25 | 1.5% | — | ||
| Q3 25 | 0.4% | 0.0% | ||
| Q2 25 | 0.2% | — | ||
| Q1 25 | 0.8% | — | ||
| Q4 24 | 2.5% | — | ||
| Q3 24 | 0.5% | — | ||
| Q2 24 | 0.5% | — | ||
| Q1 24 | 0.5% | — |
| Q4 25 | 4.55× | — | ||
| Q3 25 | 0.41× | 1.19× | ||
| Q2 25 | 2.19× | — | ||
| Q1 25 | 2.32× | — | ||
| Q4 24 | 128.41× | — | ||
| Q3 24 | 18.33× | — | ||
| Q2 24 | -0.54× | — | ||
| Q1 24 | 3.82× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HCI
| Insurance Operation | $218.3M | 89% |
| Reciprocal Exchange Operation | $27.0M | 11% |
IDYA
Segment breakdown not available.
